Published in Alcohol Clin Exp Res on September 08, 2008
The dopamine hypothesis of drug addiction and its potential therapeutic value. Front Psychiatry (2011) 1.08
A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients. Alcohol Clin Exp Res (2011) 1.08
The dopamine D3 receptor partial agonist CJB090 and antagonist PG01037 decrease progressive ratio responding for methamphetamine in rats with extended-access. Addict Biol (2010) 0.98
Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes. Alcohol Clin Exp Res (2012) 0.95
The effect of aripiprazole on cue-induced brain activation and drinking parameters in alcoholics. J Clin Psychopharmacol (2010) 0.93
Aripiprazole: from pharmacological profile to clinical use. Neuropsychiatr Dis Treat (2015) 0.84
Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review. Ann Gen Psychiatry (2009) 0.83
N-methyl-D-aspartate receptor antagonism has differential effects on alcohol craving and drinking in heavy drinkers. Alcohol Clin Exp Res (2015) 0.81
Adjunctive aripiprazole therapy with escitalopram in patients with co-morbid major depressive disorder and alcohol dependence: clinical and neuroimaging evidence. J Psychopharmacol (2013) 0.79
Treatment for comorbid borderline personality disorder and alcohol use disorders: a review of the evidence and future recommendations. Exp Clin Psychopharmacol (2012) 0.76
Personalizing substance use treatment based on pre-treatment impulsivity and sensation seeking: A review. Drug Alcohol Depend (2016) 0.75
Dose specific effects of olanzapine in the treatment of alcohol dependence. Psychopharmacology (Berl) (2014) 0.75
Alcohol-Induced Stimulation Mediates the Effect of a GABRA2 SNP on Alcohol Self-Administrated among Alcohol-Dependent Individuals. Alcohol Alcohol (2016) 0.75
Impulse control loss rapidly reversed by aripiprazole in a patient with concomitant bipolar disease type I and posttraumatic frontal lobe lesions. BMJ Case Rep (2011) 0.75
Emerging pharmacotherapies for alcohol use disorder. Neuropharmacology (2017) 0.75
Factor structure of the Barratt impulsiveness scale. J Clin Psychol (1995) 19.86
Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology (2001) 9.25
Decision making, impulse control and loss of willpower to resist drugs: a neurocognitive perspective. Nat Neurosci (2005) 7.65
Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict (1989) 6.58
Alcohol dependence syndrome: measurement and validation. J Abnorm Psychol (1982) 5.77
Development and validation of the Biphasic Alcohol Effects Scale. Alcohol Clin Exp Res (1993) 4.03
Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology (Berl) (2002) 3.74
Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther (2002) 3.67
Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcohol Clin Exp Res (1995) 2.92
Cue-induced activation of the striatum and medial prefrontal cortex is associated with subsequent relapse in abstinent alcoholics. Psychopharmacology (Berl) (2004) 2.69
Differential brain activity in alcoholics and social drinkers to alcohol cues: relationship to craving. Neuropsychopharmacology (2004) 2.69
Structural brain imaging of attention-deficit/hyperactivity disorder. Biol Psychiatry (2005) 2.40
Neural response to alcohol stimuli in adolescents with alcohol use disorder. Arch Gen Psychiatry (2003) 2.31
The obsessive compulsive drinking scale: A new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry (1996) 2.22
Executive and prefrontal dysfunction in unipolar depression: a review of neuropsychological and imaging evidence. Neurosci Res (2004) 2.18
A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry (2006) 2.17
Structural brain imaging evidence for multiple pathological processes at different stages of brain development in schizophrenia. Schizophr Bull (2005) 2.13
Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. J Neurosci (1998) 2.12
Recovery from alcohol problems with and without treatment: prevalence in two population surveys. Am J Public Health (1996) 2.11
Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther (2004) 2.10
Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry (1999) 2.03
Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res (2003) 1.86
Subjective responses to alcohol in sons of alcoholics and control subjects. Arch Gen Psychiatry (1984) 1.83
Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people. Arch Gen Psychiatry (2008) 1.80
Aripiprazole in schizophrenia with cocaine dependence: a pilot study. J Clin Psychopharmacol (2005) 1.79
"Loss of control" in alcoholism and drug addiction: a neuroscientific interpretation. Exp Clin Psychopharmacol (2000) 1.75
Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking. Psychopharmacology (Berl) (2004) 1.66
Behavioral neurobiology of alcohol addiction: recent advances and challenges. J Neurosci (2002) 1.62
Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology (1999) 1.60
Ethanol-associated olfactory stimuli reinstate ethanol-seeking behavior after extinction and modify extracellular dopamine levels in the nucleus accumbens. Alcohol Clin Exp Res (1999) 1.23
Aripiprazole attenuates the discriminative-stimulus and subject-rated effects of D-amphetamine in humans. Neuropsychopharmacology (2005) 1.21
Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol (2005) 1.21
Chronic ethanol consumption by C57BL/6 mice promotes tolerance to its interoceptive cues and increases extracellular dopamine, an effect blocked by naltrexone. Alcohol Clin Exp Res (2003) 1.20
Glutamate-dopamine cotransmission and reward processing in addiction. Alcohol Clin Exp Res (2006) 1.18
A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene. Neuropsychopharmacology (2002) 1.14
Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur J Pharmacol (2004) 1.13
Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers. Alcohol Clin Exp Res (2004) 1.12
Aripiprazole blocks reinstatement of cocaine seeking in an animal model of relapse. Biol Psychiatry (2006) 1.08
A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence. J Clin Psychopharmacol (2008) 1.08
Using magnetic resonance imaging and diffusion tensor imaging to assess brain damage in alcoholics. Alcohol Res Health (2003) 1.03
Current pharmacotherapies of alcoholism: a U.S. perspective. Am J Addict (2003) 1.03
Naltrexone effects on ethanol consumption and response to ethanol conditioned cues in C57BL/6 mice. Psychopharmacology (Berl) (2000) 1.00
New methodologies for pharmacological treatment trials for alcohol dependence. Alcohol Clin Exp Res (1996) 0.99
Drinking in alcoholics following an alcohol challenge research protocol. J Stud Alcohol (2000) 0.90
Central nervous changes in social dysfunction: autism, aggression, and psychopathy. Brain Res Bull (2006) 0.89
Aripiprazole reduces alcohol use. Can J Psychiatry (2005) 0.87
Effects of aripiprazole on subjective and physiological responses to alcohol. Alcohol Clin Exp Res (2008) 0.87
Discriminant analysis of the Self-Administered Alcoholism Screening Test. Alcohol Clin Exp Res (1987) 0.85
Effects of aripiprazole on alcohol intake in an animal model of high-alcohol drinking. Alcohol Alcohol (2006) 0.82
Prospective relations between social support and depression: differential direction of effects for parent and peer support? J Abnorm Psychol (2004) 2.41
Is cocaine desire reduced by N-acetylcysteine? Am J Psychiatry (2007) 2.08
Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review. Addict Biol (2012) 1.63
Gabapentin combined with naltrexone for the treatment of alcohol dependence. Am J Psychiatry (2011) 1.63
Variation in GABRA2 predicts drinking behavior in project MATCH subjects. Alcohol Clin Exp Res (2007) 1.62
Markers in the 5'-region of GABRG1 associate to alcohol dependence and are in linkage disequilibrium with markers in the adjacent GABRA2 gene. Neuropsychopharmacology (2007) 1.48
Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict (2006) 1.39
Neural correlates of craving and resisting craving for tobacco in nicotine dependent smokers. Addict Biol (2011) 1.30
Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol (2005) 1.21
Prolonged exposure therapy for combat-related posttraumatic stress disorder: an examination of treatment effectiveness for veterans of the wars in Afghanistan and Iraq. J Anxiety Disord (2010) 1.10
Telehealth service delivery for persons with alcoholism. J Telemed Telecare (2005) 1.03
Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues. Neuropsychopharmacology (2012) 1.03
Association of variants in MANEA with cocaine-related behaviors. Arch Gen Psychiatry (2009) 1.03
A double-blind evaluation of gabapentin on alcohol effects and drinking in a clinical laboratory paradigm. Alcohol Clin Exp Res (2007) 1.01
Safety and efficacy of GABAergic medications for treating alcoholism. Alcohol Clin Exp Res (2005) 1.01
Naltrexone treatment of adolescent alcoholics: an open-label pilot study. J Child Adolesc Psychopharmacol (2005) 1.01
COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms. J Stud Alcohol Suppl (2005) 0.97
Increased fasting plasma ghrelin levels during alcohol abstinence. Alcohol Alcohol (2004) 0.97
Stability of fMRI striatal response to alcohol cues: a hierarchical linear modeling approach. Neuroimage (2011) 0.97
Brain activation to cocaine cues and motivation/treatment status. Addict Biol (2012) 0.96
Association of CHRNA4 polymorphisms with smoking behavior in two populations. Am J Med Genet B Neuropsychiatr Genet (2011) 0.96
Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes. Alcohol Clin Exp Res (2012) 0.95
Novel anticonvulsants in the treatment of alcoholism. Expert Opin Investig Drugs (2005) 0.94
Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms. J Clin Psychopharmacol (2009) 0.93
Blood pressure reduction during treatment for alcohol dependence: results from the Combining Medications and Behavioral Interventions for Alcoholism (COMBINE) study. Addiction (2008) 0.92
Health service utilization before and after evidence-based treatment for PTSD. Psychol Serv (2012) 0.90
Prospective associations between brain activation to cocaine and no-go cues and cocaine relapse. Drug Alcohol Depend (2013) 0.89
Effects of naltrexone on the ethanol-induced changes in the rat central dopaminergic system. Alcohol Alcohol (2005) 0.89
Linkage analysis followed by association show NRG1 associated with cannabis dependence in African Americans. Biol Psychiatry (2012) 0.88
The use of divalproex in alcohol relapse prevention: a pilot study. Drug Alcohol Depend (2002) 0.86
Varenicline effects on drinking, craving and neural reward processing among non-treatment-seeking alcohol-dependent individuals. Psychopharmacology (Berl) (2014) 0.85
A pilot trial of neuropsychological evaluations conducted via telemedicine in the Veterans Health Administration. Telemed J E Health (2012) 0.85
Effects of divalproex on smoking cue reactivity and cessation outcomes among smokers achieving initial abstinence. Exp Clin Psychopharmacol (2012) 0.83
Recent advances in the pharmacotherapy of alcoholism. Curr Psychiatry Rep (2004) 0.83
Prolonged exposure therapy for combat-related posttraumatic stress disorder: comparing outcomes for veterans of different wars. Psychol Serv (2012) 0.83
Buprenorphine for postoperative pain following general surgery in a buprenorphine-maintained patient. Am J Psychiatry (2007) 0.83
The differential effects of medication on mood, sleep disturbance, and work ability in outpatient alcohol detoxification. Am J Addict (2002) 0.83
Functional neuroanatomy of subcomponent cognitive processes involved in verbal working memory. Int J Neurosci (2005) 0.82
Pregabalin is effective against behavioral and electrographic seizures during alcohol withdrawal. Alcohol Alcohol (2006) 0.82
Prenatal LPS increases inflammation in the substantia nigra of Gdnf heterozygous mice. Brain Pathol (2010) 0.81
The relationship between years of cocaine use and brain activation to cocaine and response inhibition cues. Addiction (2014) 0.81
Combat posttraumatic stress disorder, substance use disorders, and traumatic brain injury. J Addict Med (2009) 0.80
ACSL6 is associated with the number of cigarettes smoked and its expression is altered by chronic nicotine exposure. PLoS One (2011) 0.80
Neurocognitive performance, alcohol withdrawal, and effects of a combination of flumazenil and gabapentin in alcohol dependence. Alcohol Clin Exp Res (2011) 0.78
Impact of DCS-facilitated cue exposure therapy on brain activation to cocaine cues in cocaine dependence. Drug Alcohol Depend (2013) 0.78
Computer simulation games as an adjunct for treatment in male veterans with alcohol use disorder. J Subst Abuse Treat (2012) 0.78
Effects of a GABA-ergic medication combination and initial alcohol withdrawal severity on cue-elicited brain activation among treatment-seeking alcoholics. Psychopharmacology (Berl) (2013) 0.78
A severe case of clonidine dependence and withdrawal. J Psychiatr Pract (2003) 0.78
Biomarkers as aids to identification of relapse in alcoholic patients. Recent Dev Alcohol (2003) 0.77
Health service use among persons with comorbid bipolar and substance use disorders. Psychiatr Serv (2005) 0.77
Risk factors for delirium tremens: a retrospective chart review. Am J Addict (2006) 0.77
Acamprosate: a new tool in the battle against alcohol dependence. Neuropsychiatr Dis Treat (2006) 0.76
Complexity changes of the EEG induced by alcohol cue exposure in alcoholics and social drinkers. Alcohol Clin Exp Res (2003) 0.76
Impact of lifetime alcohol quit attempts and medicated detoxifications on time to relapse during an index alcohol detoxification. J Addict Med (2007) 0.76
Beliefs as a predictor of relapse in alcohol-dependent Turkish men. J Stud Alcohol (2005) 0.75
Challenges to medications development in treating alcohol dependence: an international perspective. Alcohol Alcohol (2004) 0.75
Roman Catholic Clergy who have sexually abused children: their perceptions of their developmental experience. Child Abuse Negl (2013) 0.75
Suicide-specific Safety in the Inpatient Psychiatric Unit. Issues Ment Health Nurs (2015) 0.75
Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status. Neuropsychopharmacology (2017) 0.75